A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study of UBX0101 in Moderate to Severe, Painful Osteoarthritis of the Knee
Latest Information Update: 30 Dec 2021
At a glance
- Drugs UBX-0101 (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors UNITY Biotechnology
- 01 Sep 2020 Status changed from active, no longer recruiting to completed.
- 17 Aug 2020 Results published in the UNITY Biotechnology Media Release.
- 17 Aug 2020 According to an UNITY Biotechnology media release, full results from this study will be presented at a future medical meeting.